Anti-HLA-DRB1 antibodies are used in the immunodetection of the protein major histocompatibility complex, class II, DR beta 1. In humans, the canonical protein has a reported length of 266 amino acid residues and a mass of 30 kDa. Its subcellular localization is in the ER, lysosomes, and cell membrane. It is reported to be expressed in professional APCs: monocyte/macrophages, dendritic cells and B cells. HLA-DRB1 is known to be involved with epidermis development and immune response pathways. Post-translational modifications have been described, including ubiquitination and glycosylation.
The HLA-DRB1 marker can be used to identify CDC1 CD141+ Myeloid Dendritic Cells, CDC2 CD1C+ Myeloid Dendritic Cells, Plasmacytoid Dendritic Cells, and Blood Vessel Endothelial Cells.* Synonyms for this target antigen include HLA-DR1B, HLA-DRB, SS1, major histocompatibility complex, class II, DR beta 1 precursor, and DRB1. Over 2200 citations in the literature describe the use of HLA-DRB1 antibodies in research. Flow Cytometry is a widely used application for these antibodies. Western Blot and Immunohistochemistry are also common applications.
*HuBMAP Human Reference Atlas v1.4